|
|
Efficacy of Shenqi Shiyiwei Granules combined with Levothyroxine Sodium Tablets in the treatment of Hashimoto thyroiditis with syndrome of yang deficiency of spleen and kidney |
JIA Wei1 WANG Fen1 WANG Can1 LU Yating2 GUO Wenlu1 LI Xiaodie1 ZHU Defa1 |
1.Department of Geriatric Endocrinology, the First Affiliated Hospital of Anhui Medical University, Anhui Province, Hefei 230022, China;
2.Department of Endocrinology and Metabolic Diseases, the First Affiliated Hospital of Anhui Medical University, Anhui Province, Hefei 230022, China
|
|
|
Abstract Objective To explore the efficacy of Shenqi Shiyiwei Granules combined with Levothyroxine Sodium Tablets in the treatment of Hashimoto thyroiditis (HT) with syndrome of yang deficiency of spleen and kidney. Methods A total of 90 HT patients with syndrome of yang deficiency of spleen and kidney admitted to the First Affiliated Hospital of Anhui Medical University from April 2020 to October 2021 were selected. Patients were divided into control 1, 2 groups, and treatment group according to random number table method, with 30 cases in each group. Control 1 group was given Levothyroxine Sodium Tablets, control 2 group was given Shenqi Shiyiwei Granules, treatment group was given Levothyroxine Sodium Tablets combined with Shenqi Shiyiwei Granules. The treatment course of the three groups was three months. The clinical efficacy and traditional Chinese medicine symptom scores, thyroid hormone indexes, thyroid antibody indexes, inflammatory factors, and lymphocyte subsets before and after treatment were compared among the three groups. Results The clinical efficacy of the treatment group was better than that of control 1 and 2 groups (P<0.05). After treatment, traditional Chinese medicine symptom scores, anti-thyroglobulin antibody, anti-thyroid peroxidase antibody, thyrotropin hormone, and interleukin-6 levels in the three groups were lower than those before treatment, and those in treatment group were lower than those in control 1 and 2 groups (P<0.05). After treatment, the CD4+/CD8+ levels in three groups were higher than those before treatment (P<0.05). After treatment, the free triiodothyronine, free thyroid hormone, CD3+, CD4+, CD8+, and interleukin-10 levels in three groups were higher than those before treatment, and those in treatment group were higher than those in control 1 and 2 groups (P<0.05). Conclusion Shenqi Shiyiwei Granules combined with Levothyroxine Sodium Tablets have significant effects in the treatment of HT with syndrome of yang deficiency of spleen and kidney, which can improve symptoms, reduce inflammatory factors, and maintain the stability of immune cells.
|
|
|
|
|
[1] 北京中西医结合学会甲状腺病专业委员会.桥本氏甲状腺炎中西医结合质量控制指标体系北京专家共识(2021版)[J].中日友好医院学报,2021,35(6):323-327.
[2] 刘莹,李昀昊,杨宏杰.桥本甲状腺炎发病机制研究进展[J].长春中医药大学学报,2017,33(4):686-688.
[3] 宁日红,宁红艳,谷丽娜,等.“脾肾益甲方”联合左甲状腺素钠片治疗脾肾阳虚型桥本氏甲状腺功能减退40例临床研究[J].江苏中医药,2022,54(3):42-45.
[4] 赵淑萍.参芪十一味颗粒联合西药治疗肺肾两虚型慢性阻塞性肺疾病稳定期临床研究[J].新中医,2021,53(18):56-59.
[5] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺炎[J].中华内科杂志,2008,47(9):784-788.
[6] 郑筱萸.中药新药临床研究指导原则:试行[M].北京:中国医药科技出版社,2002:361-385.
[7] 杜广华,徐灿坤,徐云生.桥本甲状腺炎的中西医临床研究进展[J].海南医学院学报,2021,27(14):1109-1115.
[8] 北京中西医结合学会甲状腺病专业委员会.桥本甲状腺炎中西医结合诊疗北京专家共识(2021,北京)[J].中国医药导报,2022,19(34):4-7.
[9] 杨彬婕,侯丹.软坚消瘿颗粒联合左甲状腺素钠片治疗桥本甲状腺炎伴甲状腺功能减退临床疗效[J].临床军医杂志,2020,48(3):293-295.
[10] 李心爱,商建伟,陈晓珩,等.丁治国教授治疗桥本甲状腺炎(甲状腺毒症期)的临床效果及经验探索[J].中国医药科学,2022,12(13):18-21,70.
[11] 周凯伦,王旭.从脾肾论治桥本甲状腺炎合并甲状腺功能减退[J].中国中医基础医学杂志,2018,24(2):170-172.
[12] 叶苗青,方邦江.方邦江教授治疗桥本甲状腺炎经验撷要[J].现代中西医结合杂志,2018,27(33):3689-3692.
[13] 黄俊生.参芪十一味颗粒联合重组人粒细胞刺激因子治疗化疗后白细胞减少的临床疗效观察[J].临床医学工程,2019,26(12):1667-1668.
[14] 刘丽华,吴斯淳,李晓静.桥本甲状腺炎患者血清甲状腺过氧化物酶抗体和甲状腺球蛋白抗体表达水平及诊断意义[J].实用医院临床杂志,2020,17(6):175-178.
[15] 王春,石娜,王崇高,等.桥本甲状腺炎细胞病理分级与甲状腺功能和Hb、RBC、WBC及PLT的相关性研究[J].中国实验诊断学,2021,25(12):1746-1751.
[16] 王浩东.桥本甲状腺炎甲减患者左甲状腺素钠片治疗前后甲状腺激素的变化分析[J].航空航天医学杂志,2021, 32(6):673-674.
[17] 张敏,谢承均.桥本甲状腺炎患者CD8+T淋巴细胞、甲状腺相关激素水平与患病风险及预后的关系[J].标记免疫分析与临床,2022,29(1):45-50.
[18] 白春林,何涛,肖莉,等.金水宝胶囊联合左甲状腺素片治疗桥本甲状腺炎的效果及对过氧化物酶抗体和炎症因子的影响[J].中国医药导报,2020,17(22):148-151.
[19] 马士芬,王娟红,魏威,等.IL-4及IL-6在桥本甲状腺炎中的表达及意义[J].山西医科大学学报,2018,49(12): 1483-1487.
[20] 毕建华,郝兰香,黄飞,等.桥本甲状腺炎患者外周血CD4+ CD25+ Foxp3+调节性T细胞及IL-10的检测及临床意义[J].临床和实验医学杂志,2017,16(1):38-40.
[21] 李博,耿刚.黄芪的化学成分与药理作用研究进展[J].中西医结合研究,2022,14(4):262-264.
[22] 向璐,张巧艳,赵琦明,等.黄芪-当归化学成分、药理作用及临床应用的研究进展[J].中草药,2022,53(7):2196-2213.
[23] 王文越,刘珊,吕琴,等.黄芪-当归药对益气活血药理作用研究进展[J].中国实验方剂学杂志,2021,27(6):207-216.
[24] 郑厚胜,王英平,郑斯文,等.基于网络药理学探讨人参的免疫调节机制[J].中国医院用药评价与分析,2019, 19(12):1435-1440.
[25] 刘喆,夏楠楠,刘农军,等.人参皂苷Rg1抑制滑膜细胞样成纤维细胞侵袭增殖及炎性因子释放的实验研究[J].新中医,2022,54(11):1-6.
[26] 刘倩倩,樊官伟.人参皂苷Rg3现代药理作用及作用机制的研究进展[J].中西医结合心脑血管病杂志,2022, 20(13):2375-2381.
[27] 黄琦,陈颉.人参皂苷对桥本甲状腺炎患者自身抗体及IL-17的影响[J].浙江临床医学,2021,23(9):1329- 1330,1333. |
|
|
|